Literature DB >> 21837506

[Community-acquired pneumonia].

K Dalhoff1.   

Abstract

Community-acquired pneumonia (CAP) is the most common form of severe infectious disease in developed countries. The mortality is particularly high in elderly patients. For risk stratification simple clinical scores such as the CRB-65 (confusion, respiratory rate, blood pressure, age over 65 years) are recommended. The spectrum of pathogens is characterized by Pneumococcus and Haemophilus influenzae as well as atypical and viral pathogens. Resistance plays a subordinate role in Germany. In addition to the clinical symptoms an X-ray examination is also helpful to confirm the diagnosis and biomarkers can also be useful. Microbiological investigations are not necessary in practice. Particularly in cases of uncharacteristic clinical symptoms and therapy failure there are many differential diagnoses which can be hidden behind the clinical diagnosis of pneumonia. The calculated treatment of CAP should correspond to the current recommendations in national guidelines. The options for prevention by general measures and vaccinations should be applied consistently.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837506     DOI: 10.1007/s00108-011-2860-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

1.  [The 2009/2010 pandemic].

Authors:  T Schaberg; R Burger
Journal:  Pneumologie       Date:  2010-12-02

2.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller
Journal:  Am J Respir Crit Care Med       Date:  2006-04-07       Impact factor: 21.405

3.  CRB-65 predicts death from community-acquired pneumonia.

Authors:  T T Bauer; S Ewig; R Marre; N Suttorp; T Welte
Journal:  J Intern Med       Date:  2006-07       Impact factor: 8.989

4.  Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment.

Authors:  H Kothe; T Bauer; R Marre; N Suttorp; T Welte; K Dalhoff
Journal:  Eur Respir J       Date:  2008-02-20       Impact factor: 16.671

5.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

6.  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.

Authors:  M I Restrepo; E M Mortensen; G W Waterer; R G Wunderink; J J Coalson; A Anzueto
Journal:  Eur Respir J       Date:  2008-09-03       Impact factor: 16.671

7.  Invasive aspergillosis in critically ill patients without malignancy.

Authors:  Wouter Meersseman; Stefaan J Vandecasteele; Alexander Wilmer; Eric Verbeken; Willy E Peetermans; Eric Van Wijngaerden
Journal:  Am J Respir Crit Care Med       Date:  2004-06-30       Impact factor: 21.405

8.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.

Authors:  Larry M Baddour; Victor L Yu; Keith P Klugman; Charles Feldman; Ake Ortqvist; Jordi Rello; Arthur J Morris; Carlos M Luna; David R Snydman; Wen Chien Ko; M Bernadete F Chedid; David S Hui; Antoine Andremont; Christine C C Chiou
Journal:  Am J Respir Crit Care Med       Date:  2004-06-07       Impact factor: 21.405

9.  Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors.

Authors:  H von Baum; T Welte; R Marre; N Suttorp; S Ewig
Journal:  Eur Respir J       Date:  2009-08-13       Impact factor: 16.671

10.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.

Authors:  S Ewig; N Birkner; R Strauss; E Schaefer; J Pauletzki; H Bischoff; P Schraeder; T Welte; G Hoeffken
Journal:  Thorax       Date:  2009-05-18       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.